west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "利尿" 10 results
  • 利尿剂在老年高血压治疗中的应用

    利尿剂因降压效果强,能显著降低心血管事件且价格低廉,一直被各国高血压指南和专家共识推荐为一线降压药物。在老年高血压人群中尤是如此。长期使用利尿剂有一定的不良反应,但合理的、小剂量的使用,能实现有效的降压和靶器官保护作用,避免不良事件发生。

    Release date: Export PDF Favorites Scan
  • Polyuria in Patients with COPD During Mechanical Ventilation and Its Possible Mechanism

    Objective To study polyuria during mechanical ventilation in patients with chronic obstructive pulmonary disease ( COPD) and its possible mechanisms. Methods The plasma and urine concentrations of cystatin C ( CyC) were measured by enzyme immunometric assay in 26 COPD patients who received mechanical ventilation at timepoints of 0 h, 24 h, 48 h, 72 h and 1 week. And plasma levels of atrial natriuretic factor ( ANF ) , antidiuretic hormone ( ADH) and aldosterone ( ALD) were detected byradioimmunoassay at the same time-point. The urine volume was recorded every day. The samples of 30 healthy volunteers were measured as control. Results Polyuria phenomenon was found in majority of patients in 24 to 72 hours after mechanical ventilation. At 0h, the concentrations of plasma CyC, urine CyC,plasma ANF, ADH and ALD were all increased significantly compared with those of the control, respectively [ ( 4. 87 ±0. 51) mg/L vs ( 1. 29 ±0. 27) mg/L, ( 0. 58 ±0. 13) mg/L vs ( 0. 07 ±0. 02) mg/L, ( 37. 02 ±4. 35) pmol /L vs ( 22. 51 ±1. 18) pmol /L, ( 8. 61 ±1. 43) pmol /L vs ( 0.94 ±0. 34) pmol /L, ( 925. 4 ±142. 7) pmol /L vs ( 297. 5 ±135. 8) pmol /L, all P lt; 0. 01] , then decreased gradually after mechanical ventilation. The levels of plasma CyC and ANF at 24 h, plasma ADH at 72 h, and urine CyC at 1 week were similar to those of the control( all P gt;0. 05) , respectively, except the level of plasma ALD was still higher by 1 week( P lt; 0. 05) . Conclusions Polyuria is not a rare phenomenon for COPD patients receiving mechanical ventilation. Polyuria is related to the readjustment and mal-adaptation of ADH and reninangiotensin-aldosterone-systems during mechanical ventilation.

    Release date:2016-09-14 11:25 Export PDF Favorites Scan
  • New Advance of Evidence-based Research of Hypertension in 2004

    We correct some misunderstandings of hypertension therapy and update the knowledge of hypertensive drugs by reviewing the progress of evidence-based research of hypertension in 2004.

    Release date:2016-09-07 02:25 Export PDF Favorites Scan
  • Study of the Diagnosis and Treatment of the Cerebral Salt Wasting Syndrome after Craniocerebral Injury

    目的:探讨颅脑损伤后脑耗盐综合征患者的诊断与治疗策略。方法:对我科2006~2007年收治的37例CSWS患者临床资料进行回顾性分析和总结。结果:经治疗,37例CSWS患者31例血钠恢复正常,4例死亡,无1例发生桥脑髓鞘溶解症。结论:脑耗盐综合征是颅脑损伤后患者低钠血症的最主要原因。早期明确诊断,积极稳妥补液补钠是有效治疗CSWS患者的关键。

    Release date:2016-09-08 09:56 Export PDF Favorites Scan
  • 以精神症状为首发表现伴抗利尿激素分泌不适当综合征的肺癌二例

    Release date: Export PDF Favorites Scan
  • 心力衰竭诱发慢加急性肝衰竭临床分析一例

    Release date: Export PDF Favorites Scan
  • 小剂量利尿剂在中-重度胰腺炎中的作用评价

    目的探讨小剂量利尿剂在中-重度胰腺炎治疗中的作用。 方法回顾性分析2012年1月-2013年8月62例中-重度胰腺炎患者病历资料。入院后立即给予积极液体复苏及综合治疗,使24 h尿量达到1 000 mL以上,有46例患者在24~48 h内出现呼吸>24次/min,心率>100次/min。根据患者是否使用利尿剂分为2组,对照组22例患者给予限制液体量和滴速,利尿剂组24例患者在上述方案基础上同时给予小剂量利尿剂,并统计分析两组患者的出入量、治愈率、并发症、住院周期。 结果两组平均24 h入量为利尿剂组(1 076.67±88.99)mL、对照组(1 140.45±133.75)mL,差异无统计学意义(P>0.05);平均24 h尿量为利尿剂组(1 219.17±242.05)mL、对照组(1 038.18±171.54)mL,差异有统计学意义(P<0.05)。利尿剂组24例患者短期内心率、呼吸恢复正常,其局部并发症发生率为4.2%,全身并发症的发生率为12.5%,治愈好转率为91.7%,平均住院时间为(13.88±3.79)d; 22例对照组患者其局部并发症发生率为27.3%,全身并发症的发生率为40.9%,治愈好转率为63.9%,平均住院时间为(19.09±4.68)d;除局部并发症发生率差异无统计学意义(P>0.05),其余指标组间差异均有统计学意义(P<0.05)。 结论小剂量利尿剂在中-重度胰腺炎治疗中能有效地减少并发症发生,提高疗效,缩短住院周期。

    Release date: Export PDF Favorites Scan
  • 利尿剂在高血压治疗中的地位

    利尿剂一直作为降压治疗中不可或缺的一种药物,能显著降低心血管事件发生风险,然而其作为降压一线药物还是作为联合使用药物目前仍然存在争议。同时它对新发糖尿病、脂质代谢等方面的影响也不容忽视。现结合近年来发表的相关文献,对利尿剂在降压过程中的地位与困惑进行综述,从而为降压药的选择提供一定的参考。

    Release date: Export PDF Favorites Scan
  • 甲状腺功能减退合并抗利尿激素分泌失调综合征致低钠血症一例

    Release date: Export PDF Favorites Scan
  • Research progress on the application of acetazolamide in acute decompensated heart failure

    In recent years, the potential benefits of acetazolamide in managing fluid overload in acute decompensated heart failure (ADHF) have attracted the attention of researchers. This article reviews the pharmacological mechanism of acetazolamide, how it improves patient symptoms and clinical prognosis in the treatment of heart failure, and the research progress in clinical application. The aim is to provide theoretical and research basis for clinicians to adjust and choose the comprehensive application plan of diuretics for ADHF, and to provide new ideas and directions for further research and development of new drugs targeting diuretic resistance in ADHF patients.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content